ReviewBiomolecules2025
Research Progress on Quinone Compounds for the Treatment of Hepatocellular Carcinoma.
Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Translational Pharmaceutical Perspectives on Quinones as Antioxidant and Antidiabetic Agents in Diabetes and Its Complications.Pharmaceutics · 2026Review
- Screening of a quinonoid compounds library identifies decylubiquinone as an antioxidant and anti-apoptotic agent against glucocorticoid-induced osteoporosis via CD39/CD73/adenosine axis.Bioactive materials · 2026Article
- Cooperative inhibition of mTORC1 disrupts iron-redox homeostasis and triggers ferritinophagy-dependent ferroptosis in hepatocellular carcinoma.Redox biology · 2026Article
- Evaluations of Quinone/Hydroquinone Couples Acting as Two Hydrogen Atoms Antioxidants, Radical Quenchers, and Hydrogen Atom Abstractors.Biomolecules · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is the third most common cancer worldwide, widely prevalent across many countries, and poses a serious threat to human health. With changes in its epidemiology, the incidence of HCC is expected to continue rising. As a class of organic molecules widely distributed in nature, quinone compounds possess notable antioxidant, antibacterial, and antitumor properties. This article selects several quinone compounds that have shown notable research progress in recent years and artificially categorizes them into "plant-derived quinone compounds" and "non-plant-derived quinone compounds." We then provide a detailed review of the research findings regarding HCC in vitro and in vivo experiments and clinical trials, including their potential toxic side effects. Additionally, based on the varying toxicity reduction of several selected plant-derived quinones when combined with doxorubicin, we further hypothesize that these plant-derived quinone compounds may also exert detoxifying effects on other non-plant-derived quinones discussed in this article. In summary, quinone compounds still hold significant research value and development potential in the fight against HCC. At the same time, we hope our review will provide valuable insights and inspiration for future research in this field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.